Medicinal plants remain an endless source of new drugs, new drug leads, and new chemical entities (NCEs) [1] . In developing countries, medicinal plants have been the most accessible source of medicaments and in rural areas, traditional medicine is part of the first line of treatment for common pathologies [2] . The geographical characteristics of the Isthmus of Panama are responsible for its highly diverse flora and fauna. This diversity promotes the use of plants in traditional medicine by the Amerindian groups and the rural population, which have limited access to modern drugs. Panama is a unique terrestrial bridge of great biological importance. Panamanian flora is one of the richest in the world with an estimate of 9893 different species of vascular plants, of which 1327 (13.4 %) are endemic [3] . There is a large number of nonvascular species but they have not been investigated fully. Panama has over 687 species of ferns and about 1000 species of orchids, of which 50 % are endemic. Epiphytes, lianas, and climbers are a major component of the Panamanian tropical forest. Mosses abound in moist cloud forests as well as other parts of the country. Panama is considered one of the botanical "hot spot" countries and occupies the fourth place in the world in number of vascular species [4] . The number of species per 10 000 km 2 ranks even much higher than in bigger countries like India, China, and the United States [5] . Evidence of the biomedical potential of herbal drugs used in Panamanian traditional medicine is continually being reported. Panamanian plants have been evaluated for their biological activities on a diverse range of disease targets. They have been studied inter alia as cytotoxic to cancer cell lines, antimalarial, antileishmanial, antimicrobial, antiviral, larvicidal, antioxidant, immunosupressive, acetylcholinesterase inhibitors, and antihypertensive agents [6] [7] [8] [9] [10] . Research on the highly diverse Panamanian flora proposes new economical and medicinal ventures attractive to the pharmaceutical industry. In the National Science Strategic Plan 2010-2014, a very high priority has been assigned to the study and utilization of Panamanian biodiversity as a source Abstract ! Panama is a unique terrestrial bridge of extreme biological importance. It is one of the "hot spots" and occupies the fourth place among the 25 most plant-rich countries in the world, with 13.4 % endemic species. Panamanian plants have been screened for a wide range of biological activities: as cytotoxic, brine shrimp-toxic, antiplasmodial, antimicrobial, antiviral, antioxidant, immunosuppressive, and antihypertensive agents. This review concentrates on ethnopharmacological uses of medicinal plants employed by three Amerindian groups of Panama and on selected plants with novel structures and/or interesting bioactive compounds. During the last quarter century, a total of approximately 390 compounds from 86 plants have been isolated, of which 160 are new to the literature. Most of the work reported here has been the result of many international collaborative efforts with scientists worldwide. From the results presented, it is immediately obvious that the Panamanian flora is still an untapped source of new bioactive compounds.
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Medicinal plants remain an endless source of new drugs, new drug leads, and new chemical entities (NCEs) [1] . In developing countries, medicinal plants have been the most accessible source of medicaments and in rural areas, traditional medicine is part of the first line of treatment for common pathologies [2] . The geographical characteristics of the Isthmus of Panama are responsible for its highly diverse flora and fauna. This diversity promotes the use of plants in traditional medicine by the Amerindian groups and the rural population, which have limited access to modern drugs. Panama is a unique terrestrial bridge of great biological importance. Panamanian flora is one of the richest in the world with an estimate of 9893 different species of vascular plants, of which 1327 (13.4 %) are endemic [3] . There is a large number of nonvascular species but they have not been investigated fully. Panama has over 687 species of ferns and about 1000 species of orchids, of which 50 % are endemic. Epiphytes, lianas, and climbers are a major component of the Panamanian tropical forest. Mosses abound in moist cloud forests as well as other parts of the country. Panama is considered one of the botanical "hot spot" countries and occupies the fourth place in the world in number of vascular species [4] . The number of species per 10 000 km 2 ranks even much higher than in bigger countries like India, China, and the United States [5] . Evidence of the biomedical potential of herbal drugs used in Panamanian traditional medicine is continually being reported. Panamanian plants have been evaluated for their biological activities on a diverse range of disease targets. They have been studied inter alia as cytotoxic to cancer cell lines, antimalarial, antileishmanial, antimicrobial, antiviral, larvicidal, antioxidant, immunosupressive, acetylcholinesterase inhibitors, and antihypertensive agents [6] [7] [8] [9] [10] . Research on the highly diverse Panamanian flora proposes new economical and medicinal ventures attractive to the pharmaceutical industry. In the National Science Strategic Plan 2010-2014, a very high priority has been assigned to the study and utilization of Panamanian biodiversity as a source Abstract ! Panama is a unique terrestrial bridge of extreme biological importance. It is one of the "hot spots" and occupies the fourth place among the 25 most plant-rich countries in the world, with 13.4 % endemic species. Panamanian plants have been screened for a wide range of biological activities: as cytotoxic, brine shrimp-toxic, antiplasmodial, antimicrobial, antiviral, antioxidant, immunosuppressive, and antihypertensive agents. This review concentrates on ethnopharmacological uses of medicinal plants employed by three Amerindian groups of Panama and on selected plants with novel structures and/or interesting bioactive compounds. During the last quarter century, a total of approximately 390 compounds from 86 plants have been isolated, of which 160 are new to the literature. Most of the work reported here has been the result of many international collaborative efforts with scientists worldwide. From the results presented, it is immediately obvious that the Panamanian flora is still an untapped source of new bioactive compounds.
Supporting information available at http://www.thieme-connect.de/ejournals/toc/ plantamedica of molecules for the agrochemical, pharmaceutical, food, and cosmetic industries [11] . This paper summarizes and updates two earlier reviews [6, 7] on the current available knowledge on Panamanian medicinal plants and the numerous investigations carried out during the last quarter century on their biomedical potential, resulting in identification of compounds with new chemical structures and possible new therapeutic and/or other applications.
Ethnomedical Surveys and Traditional Medicine
! Systematic studies on Panamanian flora were initially based on selecting plants for phytochemical and pharmacological studies based on ethnopharmacological uses. In Panama, the Amerindian groups and the rural population have depended on plant preparations to treat a range of ailments, and quite remarkably with a great degree of success [12] . Panama is home to five Amerindian groups: Ngöbe-Buglé, Kuna, Emberá-Wounan, Naso or Teribe, and Bri-Bri, representing 9.6 % of the total population [13] . These ethnopharmacological surveys collected a large amount of data from three major groups in Panama namely the Kunas, the Ngöbe-Buglé, and the Teribes. Among the indigenous groups of Latin America, the Kunas have been able to preserve their cultural and political autonomy by means of a robust social organization. In spite of the Panamanian government support in health care, this ethnic group relies on the use of medicinal plants to treat a variety of illnesses and to perform religious rituals. The most common health problems in this community are malnutrition, tuberculosis, pneumonia, malign tumors in conditions like albinism, and intestinal problems. From the 90 species of plants employed in their medicine and rituals (l " Table 1), 49 plants were used topically to treat skin and eyes infections and as wound healing, 24 were used internally to treat fever, pain, cold, and general weakness, and 17 plants were used in both routes. Interestingly, 19 % of the plants used in Ku-naʼs traditional medicine were related to childbirth [14] . The Ngöbe-Buglé is the largest indigenous group in Panama (65 % of the total indigenous population) [13] . During different field trips in the homeland of the Ngöbe-Buglé since the late eighties, a total of 104 medicinal plants have been collected and identified (l " Table 1 ) [15, 16] . The Teribes represent the third most important group of Amerindians in the country. The use of medicinal plants is very common in this group, and the passing of this knowledge is the responsibility of the elders. The most common applications for medicinal plants were in the treatment of colds, headache, body aches, vertigo, cramps, diarrhea, furunculosis, leishmaniasis, and snakebites. From this study, 108 plants were identified (l " Table 1 ) [17] .
Access Rights and Legal Framework
! Panama values international cooperation and is aware of the need of increased international funding and specific initiatives to support research into priority areas to investigate the potential of unexplored Panamanian biodiversity. As signatory to the Convention of the Biological Diversity (CBD), Panama encourages the objectives of the Convention: conservation of biological diversity, sustainable use of its components, and the fair and equitable sharing of the benefits arising out of the utilization of genetic resources [18], and it is aware that intel-lectual property rights "may have an influence on the implementation" of the CBD and that it is compulsory for states to cooperate in order to ensure that intellectual property rights are "supportive of and do not run counter to" the objectives of the CBD [19] . Panama has put in place legislation through the Executive Decree 257 of 17 October 2006 and regulations of Article 71 of the General Law of Environment. Recently the Executive Decree No. 25 dated 29 of April 2009 has updated the legislation and now governs the regulations concerning access to the genetic resources of Panama. For this purpose a special unit, "Unidad Nacional de Recursos Genéticos" (UNARGEN), under the supervision of the National Environmental Authority has been created [20] . According to these regulations, collection and export permits issued by UNARGEN are required for research within the country and for sending samples out of Panama. Clear distinction is made between fundamental research and bioprospection studies. Material transfer agreements have to be signed by the collaborative scientists. Provisions are set forth for indigenous rights, equitable sharing of profits, and sovereignty rights of Panama on plant material and for conservation of biodiversity. This facilitates the exchange of samples and international collaboration while at the same time complying with the CBD.
Screenings of Panamanian Plants
! It has been estimated that from a total of 300 000 identified plant species worldwide, only 6% of this total has been pharmacologically studied and only 15 % phytochemically [21] . Four approaches were used to screen Panamanian plants for further phytochemical research. Plant selection was based on chemotaxonomy, ethnopharmacological information, and random selection of plants within an area of 0.1 ha biodiversity plots in national parks and ecologically-based bioprospection. Selected Panamanian plant extracts were subjected to a range of biological screens. They were tested for toxicity, in particular against Artemia salina [22] and cancer cell lines [23] , as antimicrobial [24] , antifungal [25] , molluscicidal [6] , and DNA intercalation [26] agents, as inhibitors of protease and reverse transcriptase [27] , for antiplasmodial [28] , anti-inflammatory [29, 30] , antihyperglycemic [31] , and anti-HSV1 [27] activities, for toxicity against Aedes aegypti [31] , and as inhibitors of receptor-binding assays on endothelin ET A , angiotensin AT 1 , and neuropeptide Y Y 1 receptors [10] . Table 2 summarizes the chemical composition and corresponding biological activities of selected Panamanian plants. Phytochemical research on candidate plants chosen after biological and chemical screening has led to the isolation of numerous new compounds, many of which have a wide array of valuable biological activities. This review has concentrated on selected plants with novel structures and/or interesting bioactive compounds. l " Table 2 summarizes in alphabetical order of the families and plants, novel and known compounds isolated, and the biological activity attributed to one or more of the compounds. This table was constructed from original publications of our group and other Panamanian scientists. The most important plant families which yielded active compounds were Clusaceae, Boragina- To increase vitality in children (WP; I; K), wound healing (S; DA; K), skin rash, fever (WP; D; NB) Philodendron radiatum Schott Pain, snakebite (R; C; TB) Spathiphyllum friedrichsthalii Schott.
Isolation of Compounds from Panamanian Plants
To avoid enlargement of the uterus during pregnancy, to facilitate childbirth (F; I; K) Spathiphyllum quindiuense Engl.
To bathe sick children (WP; I; K) Xanthosoma sp.
Strong muscular and bone aches, inflammation (In; D; K) Xanthosoma helleborifolium (Jacq.) Shott.
To facilitate childbirth (T; IK; K) Xanthosoma mexicanum Liebm.
To Table 1S provides a summary of novel compounds from Panamanian flora, but not tested for biological activity. AT: Tc (163-168) [58] Swartzia simplex (Sw.) Spreng. 
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